Jetema
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Jetema is listed on KOSDAQ and classified under Health Care, Pharmaceuticals. Its market value is US$166.3M. In FY2025 it reported revenue of US$58M and operating profit of US$2.9M.
A written company profile is not available yet; the facts above come from exchange and DART data.
Jetema in five facts
Where is Jetema listed and in which sector?
Jetema (Korean name: 제테마) trades under KRX code 216080 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Pharmaceuticals.
How large is Jetema?
Its market capitalisation was US$166.3M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Jetema's latest annual revenue and operating profit?
For fiscal year 2025, Jetema reported revenue of US$58M, operating profit of US$2.9M and a net loss of US$5.6M, per its annual report on DART (data retrieved from DART on 2026-10-02). Revenue was up 12.2% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-10-02
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Report on large shareholdings (5% rule) (standard)Oct 21
- Supply contract signed
Jetema disclosed a supply contract, worth US$7.55M, about 13.1% of its recent annual revenue, running through Oct 2031.
Supply contract · Oct 15 - Supply contract signed
Jetema disclosed a supply contract, worth US$22.6M, about 39.66% of its recent annual revenue, running through Oct 2031.
Supply contract · Oct 15 - Report on large shareholdings (5% rule) (standard)Oct 12
- Report on securities held by executives/major shareholdersSep 30
- Report on large shareholdings (5% rule) (standard)Sep 30
- Report on securities held by executives/major shareholdersSep 30
- Report on securities held by executives/major shareholdersSep 28
- Report on securities held by executives/major shareholdersSep 28
- Report on securities held by executives/major shareholdersSep 21
- Report on large shareholdings (5% rule) (standard)Sep 15
- Report on large shareholdings (5% rule) (standard)Sep 4
- Report on securities held by executives/major shareholdersSep 4
- Report on securities held by executives/major shareholdersSep 4
- Report on securities held by executives/major shareholdersSep 1
- Report on securities held by executives/major shareholdersSep 1
- Supply contract signed
Jetema disclosed a supply contract, worth US$10.6M, about 19.51% of its recent annual revenue, running through Aug 2027.
Supply contract · Aug 13 - [Attachment amended] Material event report (convertible bonds)Capital raise · Jul 7
- Material event report (rights offering)
Jetema disclosed convertible bonds to raise US$4.55M, about 3.1% of its market value.
Capital raise · Jun 19 - Material event report (convertible bonds)
Jetema disclosed convertible bonds to raise US$15M, about 10.3% of its market value.
Capital raise · Jun 19 - Change of 30% or more in revenue or profit/loss structure (15% for large companies)
Jetema reported consolidated results for FY2025: revenue of US$52.5M (+12.23% year on year), operating profit of US$2.61M (−7.1% year on year) and a net loss of US$5.08M.
Earnings · Mar 10